Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 13/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.56 |
| ▸ | DPP4 | P27487 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.56 |
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | STAT6 | P42226 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.56 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028190 | 1.00 | AHCY (0.70) | AHCYADORA3ADORA2BDPP4MEN1 | |
| SCHEMBL630675 | 0.82 | AHCY (1.00) | AHCYADORA3ADORA2A | |
| SCHEMBL12280626 | 0.82 | AHCY (1.00) | AHCYADORA3ADORA2A | |
| SCHEMBL2418669 | 0.82 | AHCY (1.00) | AHCYADORA3ADORA2A | |
| SCHEMBL29767847 | 0.82 | AHCY (1.00) | AHCYADORA3ADORA2A | |
| SCHEMBL10010471 | 0.82 | AHCY (1.00) | AHCYADORA3ADORA2A | |
| SCHEMBL29374741 | 0.82 | AHCY (1.00) | AHCYADORA3ADORA2A | |
| SCHEMBL4953719 | 0.78 | ALDH1A1 (0.52) | AHCYADORA3MAPK1 | |
| SCHEMBL4898499 | 0.78 | ADCY5 (0.60) | AHCYADORA2B | |
| SCHEMBL7588460 | 0.78 | ADCY5 (0.60) | AHCYADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261905-A1 | Modified Nucleosides for Rna Interference | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-10-23 | — | — | US | disclosed |
| US-20080261905-A1 | Modified Nucleosides for Rna Interference | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-10-23 | — | — | US | disclosed |
| US-20080261905-A1 | Modified Nucleosides for Rna Interference | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261905-A1 | Modified Nucleosides for Rna Interference | ADAR, RNASEL, RNGTT | AHCY 313/4885ADORA3 70/4885ADORA2B 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.